nodes	percent_of_prediction	percent_of_DWPC	metapath
Risedronate—FDPS—SREBP signalling—SCD—liver cancer	0.0137	0.0621	CbGpPWpGaD
Risedronate—PTGS2—Prostaglandin Synthesis and Regulation—ANXA4—liver cancer	0.0109	0.0492	CbGpPWpGaD
Risedronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—liver cancer	0.00767	0.0347	CbGpPWpGaD
Risedronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT8—liver cancer	0.00727	0.0329	CbGpPWpGaD
Risedronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—liver cancer	0.00664	0.0301	CbGpPWpGaD
Risedronate—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—liver cancer	0.00663	0.03	CbGpPWpGaD
Risedronate—FDPS—Activation of gene expression by SREBF (SREBP)—PPARA—liver cancer	0.0064	0.029	CbGpPWpGaD
Risedronate—PTGS2—Prostaglandin Synthesis and Regulation—ANXA5—liver cancer	0.00623	0.0282	CbGpPWpGaD
Risedronate—PTGS2—Prostaglandin Synthesis and Regulation—ANXA2—liver cancer	0.0057	0.0258	CbGpPWpGaD
Risedronate—FDPS—Regulation of cholesterol biosynthesis by SREBP (SREBF)—PPARA—liver cancer	0.00511	0.0231	CbGpPWpGaD
Risedronate—PTGS2—Selenium Micronutrient Network—EPT1—liver cancer	0.00367	0.0166	CbGpPWpGaD
Risedronate—Herpes zoster—Doxorubicin—liver cancer	0.00353	0.00453	CcSEcCtD
Risedronate—Immune system disorder—Sorafenib—liver cancer	0.00353	0.00453	CcSEcCtD
Risedronate—Mediastinal disorder—Sorafenib—liver cancer	0.00352	0.00452	CcSEcCtD
Risedronate—Arrhythmia—Sorafenib—liver cancer	0.00349	0.00448	CcSEcCtD
Risedronate—Amblyopia—Doxorubicin—liver cancer	0.00344	0.00442	CcSEcCtD
Risedronate—PTGS2—Overview of nanoparticle effects—HMOX1—liver cancer	0.00344	0.0156	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.00344	0.0156	CbGpPWpGaD
Risedronate—Mental disorder—Sorafenib—liver cancer	0.00342	0.00439	CcSEcCtD
Risedronate—FDPS—SREBP signalling—PPARG—liver cancer	0.00342	0.0155	CbGpPWpGaD
Risedronate—Otitis media—Doxorubicin—liver cancer	0.00342	0.00438	CcSEcCtD
Risedronate—Malnutrition—Sorafenib—liver cancer	0.0034	0.00436	CcSEcCtD
Risedronate—Cardiovascular disorder—Epirubicin—liver cancer	0.00327	0.0042	CcSEcCtD
Risedronate—Muscle spasms—Sorafenib—liver cancer	0.00327	0.00419	CcSEcCtD
Risedronate—PTGS2—Eicosanoid Synthesis—GGT1—liver cancer	0.00322	0.0146	CbGpPWpGaD
Risedronate—Bone disorder—Epirubicin—liver cancer	0.00318	0.00408	CcSEcCtD
Risedronate—Arthropathy—Epirubicin—liver cancer	0.00316	0.00406	CcSEcCtD
Risedronate—Anaemia—Sorafenib—liver cancer	0.00314	0.00403	CcSEcCtD
Risedronate—Cough increased—Epirubicin—liver cancer	0.00314	0.00403	CcSEcCtD
Risedronate—Hypocalcaemia—Epirubicin—liver cancer	0.00314	0.00403	CcSEcCtD
Risedronate—Glossitis—Epirubicin—liver cancer	0.00312	0.004	CcSEcCtD
Risedronate—Angioedema—Sorafenib—liver cancer	0.00311	0.00399	CcSEcCtD
Risedronate—Syncope—Sorafenib—liver cancer	0.00305	0.00391	CcSEcCtD
Risedronate—Ulcer—Epirubicin—liver cancer	0.00304	0.0039	CcSEcCtD
Risedronate—Cardiovascular disorder—Doxorubicin—liver cancer	0.00303	0.00388	CcSEcCtD
Risedronate—Bone pain—Epirubicin—liver cancer	0.003	0.00385	CcSEcCtD
Risedronate—Loss of consciousness—Sorafenib—liver cancer	0.00299	0.00383	CcSEcCtD
Risedronate—Cough—Sorafenib—liver cancer	0.00297	0.00381	CcSEcCtD
Risedronate—Inflammation—Epirubicin—liver cancer	0.00296	0.0038	CcSEcCtD
Risedronate—Bone disorder—Doxorubicin—liver cancer	0.00294	0.00378	CcSEcCtD
Risedronate—Hypertension—Sorafenib—liver cancer	0.00294	0.00377	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—AHR—liver cancer	0.00293	0.0133	CbGpPWpGaD
Risedronate—Arthropathy—Doxorubicin—liver cancer	0.00292	0.00375	CcSEcCtD
Risedronate—Musculoskeletal pain—Epirubicin—liver cancer	0.00291	0.00373	CcSEcCtD
Risedronate—Neck pain—Epirubicin—liver cancer	0.00291	0.00373	CcSEcCtD
Risedronate—Hypocalcaemia—Doxorubicin—liver cancer	0.0029	0.00373	CcSEcCtD
Risedronate—Cough increased—Doxorubicin—liver cancer	0.0029	0.00373	CcSEcCtD
Risedronate—Myalgia—Sorafenib—liver cancer	0.00289	0.00371	CcSEcCtD
Risedronate—Arthralgia—Sorafenib—liver cancer	0.00289	0.00371	CcSEcCtD
Risedronate—Glossitis—Doxorubicin—liver cancer	0.00289	0.0037	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00287	0.00369	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—NFE2L2—liver cancer	0.00285	0.0129	CbGpPWpGaD
Risedronate—Dry mouth—Sorafenib—liver cancer	0.00283	0.00363	CcSEcCtD
Risedronate—Eructation—Epirubicin—liver cancer	0.00282	0.00362	CcSEcCtD
Risedronate—Ulcer—Doxorubicin—liver cancer	0.00281	0.00361	CcSEcCtD
Risedronate—Cystitis noninfective—Epirubicin—liver cancer	0.00281	0.0036	CcSEcCtD
Risedronate—Influenza like illness—Epirubicin—liver cancer	0.00279	0.00358	CcSEcCtD
Risedronate—Bone pain—Doxorubicin—liver cancer	0.00278	0.00356	CcSEcCtD
Risedronate—Cystitis—Epirubicin—liver cancer	0.00278	0.00356	CcSEcCtD
Risedronate—Colitis—Epirubicin—liver cancer	0.00276	0.00354	CcSEcCtD
Risedronate—Infection—Sorafenib—liver cancer	0.00276	0.00354	CcSEcCtD
Risedronate—Inflammation—Doxorubicin—liver cancer	0.00274	0.00352	CcSEcCtD
Risedronate—Shock—Sorafenib—liver cancer	0.00273	0.0035	CcSEcCtD
Risedronate—Nervous system disorder—Sorafenib—liver cancer	0.00272	0.00349	CcSEcCtD
Risedronate—FDPS—SREBP signalling—MTOR—liver cancer	0.00271	0.0123	CbGpPWpGaD
Risedronate—Skin disorder—Sorafenib—liver cancer	0.00269	0.00346	CcSEcCtD
Risedronate—Musculoskeletal pain—Doxorubicin—liver cancer	0.00269	0.00345	CcSEcCtD
Risedronate—Neck pain—Doxorubicin—liver cancer	0.00269	0.00345	CcSEcCtD
Risedronate—Dry eye—Epirubicin—liver cancer	0.00265	0.00341	CcSEcCtD
Risedronate—Cramps of lower extremities—Epirubicin—liver cancer	0.00264	0.00339	CcSEcCtD
Risedronate—Oesophagitis—Epirubicin—liver cancer	0.00263	0.00337	CcSEcCtD
Risedronate—Eructation—Doxorubicin—liver cancer	0.00261	0.00335	CcSEcCtD
Risedronate—Bladder pain—Epirubicin—liver cancer	0.0026	0.00333	CcSEcCtD
Risedronate—Neoplasm—Epirubicin—liver cancer	0.0026	0.00333	CcSEcCtD
Risedronate—Ecchymosis—Epirubicin—liver cancer	0.0026	0.00333	CcSEcCtD
Risedronate—Cystitis noninfective—Doxorubicin—liver cancer	0.0026	0.00333	CcSEcCtD
Risedronate—PTGS2—S1P1 pathway—KDR—liver cancer	0.00258	0.0117	CbGpPWpGaD
Risedronate—Influenza like illness—Doxorubicin—liver cancer	0.00258	0.00331	CcSEcCtD
Risedronate—Cystitis—Doxorubicin—liver cancer	0.00257	0.0033	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—liver cancer	0.00256	0.0116	CbGpPWpGaD
Risedronate—Colitis—Doxorubicin—liver cancer	0.00255	0.00328	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00253	0.00324	CcSEcCtD
Risedronate—Hypertonia—Epirubicin—liver cancer	0.00252	0.00323	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—EFNB2—liver cancer	0.00251	0.0114	CbGpPWpGaD
Risedronate—Dyspnoea—Sorafenib—liver cancer	0.00247	0.00317	CcSEcCtD
Risedronate—Dry eye—Doxorubicin—liver cancer	0.00246	0.00315	CcSEcCtD
Risedronate—Cramps of lower extremities—Doxorubicin—liver cancer	0.00244	0.00313	CcSEcCtD
Risedronate—Dyspepsia—Sorafenib—liver cancer	0.00244	0.00313	CcSEcCtD
Risedronate—Oesophagitis—Doxorubicin—liver cancer	0.00243	0.00312	CcSEcCtD
Risedronate—Ecchymosis—Doxorubicin—liver cancer	0.0024	0.00309	CcSEcCtD
Risedronate—Neoplasm—Doxorubicin—liver cancer	0.0024	0.00309	CcSEcCtD
Risedronate—Bladder pain—Doxorubicin—liver cancer	0.0024	0.00309	CcSEcCtD
Risedronate—Gastrointestinal disorder—Sorafenib—liver cancer	0.0024	0.00307	CcSEcCtD
Risedronate—PTGS2—Arachidonic acid metabolism—HPGDS—liver cancer	0.00239	0.0108	CbGpPWpGaD
Risedronate—Fatigue—Sorafenib—liver cancer	0.00239	0.00307	CcSEcCtD
Risedronate—Pain—Sorafenib—liver cancer	0.00237	0.00304	CcSEcCtD
Risedronate—Constipation—Sorafenib—liver cancer	0.00237	0.00304	CcSEcCtD
Risedronate—Hypertonia—Doxorubicin—liver cancer	0.00233	0.00299	CcSEcCtD
Risedronate—Gastrointestinal pain—Sorafenib—liver cancer	0.00227	0.00291	CcSEcCtD
Risedronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—CSF2—liver cancer	0.00226	0.0102	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.00222	0.01	CbGpPWpGaD
Risedronate—Urticaria—Sorafenib—liver cancer	0.0022	0.00283	CcSEcCtD
Risedronate—Abdominal pain—Sorafenib—liver cancer	0.00219	0.00281	CcSEcCtD
Risedronate—Body temperature increased—Sorafenib—liver cancer	0.00219	0.00281	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.00214	0.00968	CbGpPWpGaD
Risedronate—PTGS2—Overview of nanoparticle effects—PIK3CD—liver cancer	0.00209	0.00948	CbGpPWpGaD
Risedronate—Pain in extremity—Epirubicin—liver cancer	0.00209	0.00268	CcSEcCtD
Risedronate—Osteoarthritis—Epirubicin—liver cancer	0.00209	0.00268	CcSEcCtD
Risedronate—Hypersensitivity—Sorafenib—liver cancer	0.00204	0.00262	CcSEcCtD
Risedronate—Asthenia—Sorafenib—liver cancer	0.00199	0.00255	CcSEcCtD
Risedronate—Pruritus—Sorafenib—liver cancer	0.00196	0.00252	CcSEcCtD
Risedronate—Osteoarthritis—Doxorubicin—liver cancer	0.00193	0.00248	CcSEcCtD
Risedronate—Pain in extremity—Doxorubicin—liver cancer	0.00193	0.00248	CcSEcCtD
Risedronate—Liver function test abnormal—Epirubicin—liver cancer	0.00193	0.00247	CcSEcCtD
Risedronate—Abdominal pain upper—Epirubicin—liver cancer	0.00191	0.00245	CcSEcCtD
Risedronate—Diarrhoea—Sorafenib—liver cancer	0.0019	0.00244	CcSEcCtD
Risedronate—Breast disorder—Epirubicin—liver cancer	0.00189	0.00242	CcSEcCtD
Risedronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—liver cancer	0.00187	0.00847	CbGpPWpGaD
Risedronate—Nasopharyngitis—Epirubicin—liver cancer	0.00187	0.00239	CcSEcCtD
Risedronate—Gastritis—Epirubicin—liver cancer	0.00185	0.00237	CcSEcCtD
Risedronate—Muscular weakness—Epirubicin—liver cancer	0.00184	0.00236	CcSEcCtD
Risedronate—Dizziness—Sorafenib—liver cancer	0.00183	0.00235	CcSEcCtD
Risedronate—Abdominal distension—Epirubicin—liver cancer	0.00182	0.00233	CcSEcCtD
Risedronate—Influenza—Epirubicin—liver cancer	0.0018	0.00231	CcSEcCtD
Risedronate—Asthma—Epirubicin—liver cancer	0.0018	0.00231	CcSEcCtD
Risedronate—PTGS2—Arachidonic acid metabolism—GGT1—liver cancer	0.00179	0.00812	CbGpPWpGaD
Risedronate—Liver function test abnormal—Doxorubicin—liver cancer	0.00178	0.00229	CcSEcCtD
Risedronate—Vomiting—Sorafenib—liver cancer	0.00176	0.00226	CcSEcCtD
Risedronate—Abdominal pain upper—Doxorubicin—liver cancer	0.00176	0.00226	CcSEcCtD
Risedronate—Angina pectoris—Epirubicin—liver cancer	0.00176	0.00225	CcSEcCtD
Risedronate—Rash—Sorafenib—liver cancer	0.00175	0.00224	CcSEcCtD
Risedronate—Dermatitis—Sorafenib—liver cancer	0.00175	0.00224	CcSEcCtD
Risedronate—Breast disorder—Doxorubicin—liver cancer	0.00174	0.00224	CcSEcCtD
Risedronate—Headache—Sorafenib—liver cancer	0.00174	0.00223	CcSEcCtD
Risedronate—Bronchitis—Epirubicin—liver cancer	0.00173	0.00223	CcSEcCtD
Risedronate—Nasopharyngitis—Doxorubicin—liver cancer	0.00173	0.00222	CcSEcCtD
Risedronate—Gastritis—Doxorubicin—liver cancer	0.00171	0.00219	CcSEcCtD
Risedronate—Muscular weakness—Doxorubicin—liver cancer	0.0017	0.00218	CcSEcCtD
Risedronate—Abdominal distension—Doxorubicin—liver cancer	0.00168	0.00216	CcSEcCtD
Risedronate—Upper respiratory tract infection—Epirubicin—liver cancer	0.00168	0.00215	CcSEcCtD
Risedronate—Influenza—Doxorubicin—liver cancer	0.00167	0.00214	CcSEcCtD
Risedronate—Asthma—Doxorubicin—liver cancer	0.00167	0.00214	CcSEcCtD
Risedronate—FDPS—SREBP signalling—PIK3CA—liver cancer	0.00166	0.0075	CbGpPWpGaD
Risedronate—Nausea—Sorafenib—liver cancer	0.00165	0.00211	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.00163	0.0074	CbGpPWpGaD
Risedronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—liver cancer	0.00163	0.0074	CbGpPWpGaD
Risedronate—FDPS—Metabolism—UGDH—liver cancer	0.00163	0.00738	CbGpPWpGaD
Risedronate—Angina pectoris—Doxorubicin—liver cancer	0.00163	0.00209	CcSEcCtD
Risedronate—PTGS2—Selenium Micronutrient Network—GPX3—liver cancer	0.00162	0.00734	CbGpPWpGaD
Risedronate—Pneumonia—Epirubicin—liver cancer	0.00162	0.00208	CcSEcCtD
Risedronate—Infestation NOS—Epirubicin—liver cancer	0.00161	0.00206	CcSEcCtD
Risedronate—Infestation—Epirubicin—liver cancer	0.00161	0.00206	CcSEcCtD
Risedronate—Bronchitis—Doxorubicin—liver cancer	0.0016	0.00206	CcSEcCtD
Risedronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—MAPK14—liver cancer	0.00158	0.00714	CbGpPWpGaD
Risedronate—Conjunctivitis—Epirubicin—liver cancer	0.00156	0.00201	CcSEcCtD
Risedronate—Urinary tract infection—Epirubicin—liver cancer	0.00156	0.00201	CcSEcCtD
Risedronate—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00155	0.00199	CcSEcCtD
Risedronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—liver cancer	0.00155	0.007	CbGpPWpGaD
Risedronate—FDPS—Metabolism—EPT1—liver cancer	0.00153	0.00694	CbGpPWpGaD
Risedronate—Hepatobiliary disease—Epirubicin—liver cancer	0.00152	0.00195	CcSEcCtD
Risedronate—Sinusitis—Epirubicin—liver cancer	0.00151	0.00194	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—CYP1A1—liver cancer	0.0015	0.00679	CbGpPWpGaD
Risedronate—Pneumonia—Doxorubicin—liver cancer	0.0015	0.00192	CcSEcCtD
Risedronate—Infestation—Doxorubicin—liver cancer	0.00149	0.00191	CcSEcCtD
Risedronate—Infestation NOS—Doxorubicin—liver cancer	0.00149	0.00191	CcSEcCtD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CSF2—liver cancer	0.00146	0.00662	CbGpPWpGaD
Risedronate—FDPS—Metabolism—TAT—liver cancer	0.00145	0.00658	CbGpPWpGaD
Risedronate—Haemoglobin—Epirubicin—liver cancer	0.00145	0.00186	CcSEcCtD
Risedronate—Rhinitis—Epirubicin—liver cancer	0.00145	0.00186	CcSEcCtD
Risedronate—Urinary tract infection—Doxorubicin—liver cancer	0.00145	0.00186	CcSEcCtD
Risedronate—Conjunctivitis—Doxorubicin—liver cancer	0.00145	0.00186	CcSEcCtD
Risedronate—Haemorrhage—Epirubicin—liver cancer	0.00144	0.00185	CcSEcCtD
Risedronate—Pharyngitis—Epirubicin—liver cancer	0.00143	0.00184	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.00143	0.00647	CbGpPWpGaD
Risedronate—Urinary tract disorder—Epirubicin—liver cancer	0.00143	0.00183	CcSEcCtD
Risedronate—PTGS2—S1P1 pathway—VEGFA—liver cancer	0.00142	0.00645	CbGpPWpGaD
Risedronate—Oedema peripheral—Epirubicin—liver cancer	0.00142	0.00182	CcSEcCtD
Risedronate—Connective tissue disorder—Epirubicin—liver cancer	0.00142	0.00182	CcSEcCtD
Risedronate—Urethral disorder—Epirubicin—liver cancer	0.00141	0.00182	CcSEcCtD
Risedronate—Hepatobiliary disease—Doxorubicin—liver cancer	0.00141	0.00181	CcSEcCtD
Risedronate—PTGS2—Arachidonic acid metabolism—CYP1A1—liver cancer	0.0014	0.00635	CbGpPWpGaD
Risedronate—Sinusitis—Doxorubicin—liver cancer	0.0014	0.00179	CcSEcCtD
Risedronate—FDPS—SREBP signalling—AKT1—liver cancer	0.00135	0.00612	CbGpPWpGaD
Risedronate—Eye disorder—Epirubicin—liver cancer	0.00135	0.00173	CcSEcCtD
Risedronate—Tinnitus—Epirubicin—liver cancer	0.00135	0.00173	CcSEcCtD
Risedronate—Haemoglobin—Doxorubicin—liver cancer	0.00134	0.00172	CcSEcCtD
Risedronate—Cardiac disorder—Epirubicin—liver cancer	0.00134	0.00172	CcSEcCtD
Risedronate—Rhinitis—Doxorubicin—liver cancer	0.00134	0.00172	CcSEcCtD
Risedronate—Haemorrhage—Doxorubicin—liver cancer	0.00134	0.00171	CcSEcCtD
Risedronate—Pharyngitis—Doxorubicin—liver cancer	0.00133	0.0017	CcSEcCtD
Risedronate—Urinary tract disorder—Doxorubicin—liver cancer	0.00132	0.00169	CcSEcCtD
Risedronate—Oedema peripheral—Doxorubicin—liver cancer	0.00132	0.00169	CcSEcCtD
Risedronate—Connective tissue disorder—Doxorubicin—liver cancer	0.00131	0.00168	CcSEcCtD
Risedronate—Angiopathy—Epirubicin—liver cancer	0.00131	0.00168	CcSEcCtD
Risedronate—Urethral disorder—Doxorubicin—liver cancer	0.00131	0.00168	CcSEcCtD
Risedronate—Immune system disorder—Epirubicin—liver cancer	0.0013	0.00167	CcSEcCtD
Risedronate—Mediastinal disorder—Epirubicin—liver cancer	0.0013	0.00167	CcSEcCtD
Risedronate—Arrhythmia—Epirubicin—liver cancer	0.00129	0.00165	CcSEcCtD
Risedronate—Mental disorder—Epirubicin—liver cancer	0.00126	0.00162	CcSEcCtD
Risedronate—Malnutrition—Epirubicin—liver cancer	0.00126	0.00161	CcSEcCtD
Risedronate—Eye disorder—Doxorubicin—liver cancer	0.00125	0.0016	CcSEcCtD
Risedronate—Tinnitus—Doxorubicin—liver cancer	0.00125	0.0016	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—ESR1—liver cancer	0.00124	0.00563	CbGpPWpGaD
Risedronate—Cardiac disorder—Doxorubicin—liver cancer	0.00124	0.00159	CcSEcCtD
Risedronate—Flatulence—Epirubicin—liver cancer	0.00124	0.00159	CcSEcCtD
Risedronate—PTGS2—Overview of nanoparticle effects—TNF—liver cancer	0.00122	0.00553	CbGpPWpGaD
Risedronate—Back pain—Epirubicin—liver cancer	0.00122	0.00156	CcSEcCtD
Risedronate—Angiopathy—Doxorubicin—liver cancer	0.00121	0.00155	CcSEcCtD
Risedronate—Muscle spasms—Epirubicin—liver cancer	0.00121	0.00155	CcSEcCtD
Risedronate—Immune system disorder—Doxorubicin—liver cancer	0.00121	0.00155	CcSEcCtD
Risedronate—Mediastinal disorder—Doxorubicin—liver cancer	0.0012	0.00154	CcSEcCtD
Risedronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—liver cancer	0.00119	0.00541	CbGpPWpGaD
Risedronate—Arrhythmia—Doxorubicin—liver cancer	0.00119	0.00153	CcSEcCtD
Risedronate—Mental disorder—Doxorubicin—liver cancer	0.00117	0.0015	CcSEcCtD
Risedronate—Malnutrition—Doxorubicin—liver cancer	0.00116	0.00149	CcSEcCtD
Risedronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—liver cancer	0.00116	0.00527	CbGpPWpGaD
Risedronate—Anaemia—Epirubicin—liver cancer	0.00116	0.00149	CcSEcCtD
Risedronate—Flatulence—Doxorubicin—liver cancer	0.00115	0.00147	CcSEcCtD
Risedronate—PTGS2—Selenium Micronutrient Network—GGT1—liver cancer	0.00114	0.00516	CbGpPWpGaD
Risedronate—Vertigo—Epirubicin—liver cancer	0.00113	0.00145	CcSEcCtD
Risedronate—Syncope—Epirubicin—liver cancer	0.00113	0.00145	CcSEcCtD
Risedronate—Back pain—Doxorubicin—liver cancer	0.00112	0.00144	CcSEcCtD
Risedronate—Muscle spasms—Doxorubicin—liver cancer	0.00112	0.00143	CcSEcCtD
Risedronate—Loss of consciousness—Epirubicin—liver cancer	0.0011	0.00142	CcSEcCtD
Risedronate—Cough—Epirubicin—liver cancer	0.0011	0.00141	CcSEcCtD
Risedronate—Hypertension—Epirubicin—liver cancer	0.00108	0.00139	CcSEcCtD
Risedronate—Anaemia—Doxorubicin—liver cancer	0.00107	0.00138	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—FST—liver cancer	0.00107	0.00487	CbGpPWpGaD
Risedronate—Chest pain—Epirubicin—liver cancer	0.00107	0.00137	CcSEcCtD
Risedronate—Arthralgia—Epirubicin—liver cancer	0.00107	0.00137	CcSEcCtD
Risedronate—Myalgia—Epirubicin—liver cancer	0.00107	0.00137	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.00107	0.00484	CbGpPWpGaD
Risedronate—Anxiety—Epirubicin—liver cancer	0.00107	0.00137	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00106	0.00136	CcSEcCtD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—liver cancer	0.00106	0.0048	CbGpPWpGaD
Risedronate—Dry mouth—Epirubicin—liver cancer	0.00105	0.00134	CcSEcCtD
Risedronate—Vertigo—Doxorubicin—liver cancer	0.00104	0.00134	CcSEcCtD
Risedronate—Syncope—Doxorubicin—liver cancer	0.00104	0.00134	CcSEcCtD
Risedronate—Loss of consciousness—Doxorubicin—liver cancer	0.00102	0.00131	CcSEcCtD
Risedronate—Infection—Epirubicin—liver cancer	0.00102	0.00131	CcSEcCtD
Risedronate—Cough—Doxorubicin—liver cancer	0.00101	0.0013	CcSEcCtD
Risedronate—Shock—Epirubicin—liver cancer	0.00101	0.00129	CcSEcCtD
Risedronate—Nervous system disorder—Epirubicin—liver cancer	0.00101	0.00129	CcSEcCtD
Risedronate—Hypertension—Doxorubicin—liver cancer	0.001	0.00129	CcSEcCtD
Risedronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—liver cancer	0.001	0.00453	CbGpPWpGaD
Risedronate—Skin disorder—Epirubicin—liver cancer	0.000996	0.00128	CcSEcCtD
Risedronate—Chest pain—Doxorubicin—liver cancer	0.00099	0.00127	CcSEcCtD
Risedronate—Myalgia—Doxorubicin—liver cancer	0.00099	0.00127	CcSEcCtD
Risedronate—Arthralgia—Doxorubicin—liver cancer	0.00099	0.00127	CcSEcCtD
Risedronate—FDPS—Metabolism—CPT1B—liver cancer	0.000987	0.00447	CbGpPWpGaD
Risedronate—FDPS—Metabolism—GLUL—liver cancer	0.000987	0.00447	CbGpPWpGaD
Risedronate—Anxiety—Doxorubicin—liver cancer	0.000986	0.00127	CcSEcCtD
Risedronate—PTGS2—Overview of nanoparticle effects—IL6—liver cancer	0.000985	0.00446	CbGpPWpGaD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000983	0.00126	CcSEcCtD
Risedronate—PTGS2—C-MYB transcription factor network—GSTM1—liver cancer	0.000976	0.00442	CbGpPWpGaD
Risedronate—Dry mouth—Doxorubicin—liver cancer	0.000968	0.00124	CcSEcCtD
Risedronate—FDPS—Metabolism—NR1H4—liver cancer	0.000952	0.00431	CbGpPWpGaD
Risedronate—Infection—Doxorubicin—liver cancer	0.000943	0.00121	CcSEcCtD
Risedronate—FDPS—Metabolism—GSTA3—liver cancer	0.000936	0.00424	CbGpPWpGaD
Risedronate—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000934	0.0012	CcSEcCtD
Risedronate—Shock—Doxorubicin—liver cancer	0.000933	0.0012	CcSEcCtD
Risedronate—Nervous system disorder—Doxorubicin—liver cancer	0.00093	0.00119	CcSEcCtD
Risedronate—Insomnia—Epirubicin—liver cancer	0.000927	0.00119	CcSEcCtD
Risedronate—Skin disorder—Doxorubicin—liver cancer	0.000922	0.00118	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—RAF1—liver cancer	0.000921	0.00417	CbGpPWpGaD
Risedronate—Paraesthesia—Epirubicin—liver cancer	0.000921	0.00118	CcSEcCtD
Risedronate—Dyspnoea—Epirubicin—liver cancer	0.000914	0.00117	CcSEcCtD
Risedronate—Dyspepsia—Epirubicin—liver cancer	0.000903	0.00116	CcSEcCtD
Risedronate—Gastrointestinal disorder—Epirubicin—liver cancer	0.000885	0.00114	CcSEcCtD
Risedronate—Fatigue—Epirubicin—liver cancer	0.000884	0.00113	CcSEcCtD
Risedronate—Constipation—Epirubicin—liver cancer	0.000877	0.00113	CcSEcCtD
Risedronate—Pain—Epirubicin—liver cancer	0.000877	0.00113	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000864	0.00111	CcSEcCtD
Risedronate—Insomnia—Doxorubicin—liver cancer	0.000858	0.0011	CcSEcCtD
Risedronate—FDPS—Metabolism—GSTA4—liver cancer	0.000856	0.00388	CbGpPWpGaD
Risedronate—Paraesthesia—Doxorubicin—liver cancer	0.000852	0.00109	CcSEcCtD
Risedronate—Dyspnoea—Doxorubicin—liver cancer	0.000846	0.00109	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—liver cancer	0.000844	0.00382	CbGpPWpGaD
Risedronate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—liver cancer	0.000839	0.0038	CbGpPWpGaD
Risedronate—Gastrointestinal pain—Epirubicin—liver cancer	0.000838	0.00108	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	0.000837	0.00379	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—HNF4A—liver cancer	0.000835	0.00378	CbGpPWpGaD
Risedronate—Dyspepsia—Doxorubicin—liver cancer	0.000835	0.00107	CcSEcCtD
Risedronate—FDPS—Metabolism—GSTA2—liver cancer	0.000834	0.00378	CbGpPWpGaD
Risedronate—PTGS2—Selenium Micronutrient Network—MTHFR—liver cancer	0.000831	0.00377	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000824	0.00373	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—liver cancer	0.000819	0.00371	CbGpPWpGaD
Risedronate—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000819	0.00105	CcSEcCtD
Risedronate—Fatigue—Doxorubicin—liver cancer	0.000818	0.00105	CcSEcCtD
Risedronate—Urticaria—Epirubicin—liver cancer	0.000815	0.00105	CcSEcCtD
Risedronate—Constipation—Doxorubicin—liver cancer	0.000811	0.00104	CcSEcCtD
Risedronate—Pain—Doxorubicin—liver cancer	0.000811	0.00104	CcSEcCtD
Risedronate—Abdominal pain—Epirubicin—liver cancer	0.000811	0.00104	CcSEcCtD
Risedronate—Body temperature increased—Epirubicin—liver cancer	0.000811	0.00104	CcSEcCtD
Risedronate—FDPS—Metabolism—GSTA1—liver cancer	0.000805	0.00365	CbGpPWpGaD
Risedronate—FDPS—Metabolism—NAT2—liver cancer	0.000796	0.0036	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	0.000779	0.00353	CbGpPWpGaD
Risedronate—Gastrointestinal pain—Doxorubicin—liver cancer	0.000776	0.000996	CcSEcCtD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—liver cancer	0.000774	0.00351	CbGpPWpGaD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—liver cancer	0.000773	0.0035	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PPARA—liver cancer	0.000765	0.00347	CbGpPWpGaD
Risedronate—FDPS—Metabolism—ALDOB—liver cancer	0.000763	0.00346	CbGpPWpGaD
Risedronate—Hypersensitivity—Epirubicin—liver cancer	0.000755	0.000969	CcSEcCtD
Risedronate—Urticaria—Doxorubicin—liver cancer	0.000754	0.000967	CcSEcCtD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—liver cancer	0.000752	0.00341	CbGpPWpGaD
Risedronate—Abdominal pain—Doxorubicin—liver cancer	0.00075	0.000962	CcSEcCtD
Risedronate—Body temperature increased—Doxorubicin—liver cancer	0.00075	0.000962	CcSEcCtD
Risedronate—Asthenia—Epirubicin—liver cancer	0.000736	0.000944	CcSEcCtD
Risedronate—PTGS2—Selenium Micronutrient Network—F2—liver cancer	0.00073	0.00331	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CRABP1—liver cancer	0.000728	0.0033	CbGpPWpGaD
Risedronate—Pruritus—Epirubicin—liver cancer	0.000725	0.000931	CcSEcCtD
Risedronate—PTGS2—Disease—APCS—liver cancer	0.000723	0.00328	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	0.000702	0.00318	CbGpPWpGaD
Risedronate—Diarrhoea—Epirubicin—liver cancer	0.000702	0.0009	CcSEcCtD
Risedronate—Hypersensitivity—Doxorubicin—liver cancer	0.000699	0.000897	CcSEcCtD
Risedronate—Asthenia—Doxorubicin—liver cancer	0.000681	0.000874	CcSEcCtD
Risedronate—Dizziness—Epirubicin—liver cancer	0.000678	0.00087	CcSEcCtD
Risedronate—Pruritus—Doxorubicin—liver cancer	0.000671	0.000861	CcSEcCtD
Risedronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—liver cancer	0.00066	0.00299	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	0.000655	0.00297	CbGpPWpGaD
Risedronate—Vomiting—Epirubicin—liver cancer	0.000652	0.000837	CcSEcCtD
Risedronate—Diarrhoea—Doxorubicin—liver cancer	0.000649	0.000833	CcSEcCtD
Risedronate—Rash—Epirubicin—liver cancer	0.000647	0.00083	CcSEcCtD
Risedronate—Dermatitis—Epirubicin—liver cancer	0.000646	0.000829	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—MYC—liver cancer	0.000646	0.00293	CbGpPWpGaD
Risedronate—Headache—Epirubicin—liver cancer	0.000642	0.000824	CcSEcCtD
Risedronate—FDPS—Metabolism—HPGDS—liver cancer	0.000636	0.00288	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PPARG—liver cancer	0.000632	0.00286	CbGpPWpGaD
Risedronate—Dizziness—Doxorubicin—liver cancer	0.000627	0.000805	CcSEcCtD
Risedronate—Nausea—Epirubicin—liver cancer	0.000609	0.000782	CcSEcCtD
Risedronate—PTGS2—Selenium Micronutrient Network—SERPINE1—liver cancer	0.000607	0.00275	CbGpPWpGaD
Risedronate—PTGS2—Selenium Micronutrient Network—ALB—liver cancer	0.000606	0.00275	CbGpPWpGaD
Risedronate—Vomiting—Doxorubicin—liver cancer	0.000603	0.000774	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—TNF—liver cancer	0.000602	0.00273	CbGpPWpGaD
Risedronate—Rash—Doxorubicin—liver cancer	0.000598	0.000768	CcSEcCtD
Risedronate—Dermatitis—Doxorubicin—liver cancer	0.000598	0.000767	CcSEcCtD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—liver cancer	0.000597	0.0027	CbGpPWpGaD
Risedronate—Headache—Doxorubicin—liver cancer	0.000594	0.000763	CcSEcCtD
Risedronate—PTGS2—C-MYB transcription factor network—CDKN2A—liver cancer	0.000589	0.00267	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	0.000576	0.00261	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—ALB—liver cancer	0.000569	0.00258	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PSMA4—liver cancer	0.000567	0.00257	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PSMD10—liver cancer	0.000567	0.00257	CbGpPWpGaD
Risedronate—Nausea—Doxorubicin—liver cancer	0.000564	0.000723	CcSEcCtD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—liver cancer	0.000563	0.00255	CbGpPWpGaD
Risedronate—FDPS—Metabolism—GOT2—liver cancer	0.000552	0.0025	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	0.000538	0.00244	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000531	0.0024	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—CDKN1B—liver cancer	0.000521	0.00236	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CYP2E1—liver cancer	0.000519	0.00235	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000512	0.00232	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	0.000507	0.0023	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	0.000502	0.00227	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—CCND1—liver cancer	0.000497	0.00225	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CYCS—liver cancer	0.000485	0.0022	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—CDKN1A—liver cancer	0.000481	0.00218	CbGpPWpGaD
Risedronate—FDPS—Metabolism—GGT1—liver cancer	0.000476	0.00216	CbGpPWpGaD
Risedronate—FDPS—Metabolism—GOT1—liver cancer	0.000476	0.00216	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	0.000462	0.00209	CbGpPWpGaD
Risedronate—FDPS—Metabolism—GSTP1—liver cancer	0.000428	0.00194	CbGpPWpGaD
Risedronate—FDPS—Metabolism—HMOX1—liver cancer	0.000422	0.00191	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.000405	0.00184	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—MYC—liver cancer	0.000399	0.00181	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.000398	0.0018	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—CDKN1B—liver cancer	0.000397	0.0018	CbGpPWpGaD
Risedronate—FDPS—Metabolism—GSTM1—liver cancer	0.000393	0.00178	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000391	0.00177	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—UGDH—liver cancer	0.00039	0.00177	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—CASP3—liver cancer	0.000389	0.00176	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—IL2—liver cancer	0.000389	0.00176	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—CCND1—liver cancer	0.000379	0.00172	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.000376	0.0017	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CYP1A1—liver cancer	0.000373	0.00169	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—KRAS—liver cancer	0.000369	0.00167	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—MMP9—liver cancer	0.000368	0.00167	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—EPT1—liver cancer	0.000367	0.00166	CbGpPWpGaD
Risedronate—PTGS2—Selenium Micronutrient Network—TNF—liver cancer	0.000358	0.00162	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—TAT—liver cancer	0.000348	0.00158	CbGpPWpGaD
Risedronate—FDPS—Metabolism—MTHFR—liver cancer	0.000347	0.00157	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000342	0.00155	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PPARA—liver cancer	0.000341	0.00154	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—HRAS—liver cancer	0.000313	0.00142	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	0.000306	0.00139	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—MYC—liver cancer	0.000304	0.00138	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—TGFB1—liver cancer	0.000303	0.00137	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	0.000295	0.00134	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PIK3CG—liver cancer	0.000292	0.00132	CbGpPWpGaD
Risedronate—PTGS2—Selenium Micronutrient Network—IL6—liver cancer	0.000289	0.00131	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—TNF—liver cancer	0.000283	0.00128	CbGpPWpGaD
Risedronate—PTGS2—Disease—LTF—liver cancer	0.000282	0.00128	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PPARG—liver cancer	0.000282	0.00128	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	0.00027	0.00122	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	0.000265	0.0012	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	0.000258	0.00117	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	0.000257	0.00117	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PIK3CD—liver cancer	0.000257	0.00116	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.000256	0.00116	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	0.000255	0.00116	CbGpPWpGaD
Risedronate—FDPS—Metabolism—ALB—liver cancer	0.000253	0.00115	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—TP53—liver cancer	0.00025	0.00113	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	0.000249	0.00113	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	0.000243	0.0011	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GLUL—liver cancer	0.000236	0.00107	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CPT1B—liver cancer	0.000236	0.00107	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—IL6—liver cancer	0.000229	0.00104	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NR1H4—liver cancer	0.000228	0.00103	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	0.000225	0.00102	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTA3—liver cancer	0.000224	0.00102	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PIK3CB—liver cancer	0.000224	0.00101	CbGpPWpGaD
Risedronate—PTGS2—Disease—ALDOB—liver cancer	0.000218	0.000988	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	0.000207	0.000937	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	0.000206	0.000935	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTA4—liver cancer	0.000205	0.000929	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	0.0002	0.000908	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTA2—liver cancer	0.0002	0.000905	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTA1—liver cancer	0.000193	0.000873	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	0.000193	0.000873	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	0.000191	0.000866	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NAT2—liver cancer	0.000191	0.000863	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	0.000183	0.00083	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ALDOB—liver cancer	0.000183	0.000828	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	0.000176	0.000795	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CRABP1—liver cancer	0.000174	0.00079	CbGpPWpGaD
Risedronate—PTGS2—Disease—ADAM17—liver cancer	0.000172	0.000781	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	0.00017	0.000769	CbGpPWpGaD
Risedronate—PTGS2—Disease—PSMA4—liver cancer	0.000162	0.000735	CbGpPWpGaD
Risedronate—PTGS2—Disease—PSMD10—liver cancer	0.000162	0.000735	CbGpPWpGaD
Risedronate—PTGS2—Disease—GOT2—liver cancer	0.000158	0.000715	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	0.000157	0.000711	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—HPGDS—liver cancer	0.000152	0.00069	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	0.000151	0.000686	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	0.000143	0.00065	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	0.000138	0.000625	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PIK3CA—liver cancer	0.000136	0.000617	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—ALB—liver cancer	0.000136	0.000617	CbGpPWpGaD
Risedronate—PTGS2—Disease—GOT1—liver cancer	0.000136	0.000617	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PSMA4—liver cancer	0.000136	0.000615	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PSMD10—liver cancer	0.000136	0.000615	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GOT2—liver cancer	0.000132	0.000598	CbGpPWpGaD
Risedronate—PTGS2—Disease—PRKCE—liver cancer	0.000126	0.000569	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP2E1—liver cancer	0.000124	0.000563	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	0.00012	0.000545	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYCS—liver cancer	0.000116	0.000526	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GOT1—liver cancer	0.000114	0.000517	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GGT1—liver cancer	0.000114	0.000517	CbGpPWpGaD
Risedronate—FDPS—Metabolism—AKT1—liver cancer	0.000111	0.000504	CbGpPWpGaD
Risedronate—PTGS2—Disease—H2AFX—liver cancer	0.00011	0.000496	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTP1—liver cancer	0.000102	0.000464	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—HMOX1—liver cancer	0.000101	0.000458	CbGpPWpGaD
Risedronate—PTGS2—Disease—MTHFR—liver cancer	9.93e-05	0.00045	CbGpPWpGaD
Risedronate—PTGS2—Disease—TERT—liver cancer	9.91e-05	0.000449	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTM1—liver cancer	9.41e-05	0.000426	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP1A1—liver cancer	8.92e-05	0.000404	CbGpPWpGaD
Risedronate—PTGS2—Disease—APC—liver cancer	8.35e-05	0.000378	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—MTHFR—liver cancer	8.32e-05	0.000377	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PPARA—liver cancer	8.16e-05	0.00037	CbGpPWpGaD
Risedronate—PTGS2—Disease—BRAF—liver cancer	7.84e-05	0.000355	CbGpPWpGaD
Risedronate—PTGS2—Disease—PIK3CD—liver cancer	7.34e-05	0.000332	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	7.33e-05	0.000332	CbGpPWpGaD
Risedronate—PTGS2—Disease—SERPINE1—liver cancer	7.26e-05	0.000329	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PIK3CG—liver cancer	6.99e-05	0.000317	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PPARG—liver cancer	6.75e-05	0.000306	CbGpPWpGaD
Risedronate—PTGS2—Disease—RAF1—liver cancer	6.55e-05	0.000297	CbGpPWpGaD
Risedronate—PTGS2—Disease—MTOR—liver cancer	6.39e-05	0.00029	CbGpPWpGaD
Risedronate—PTGS2—Disease—PIK3CB—liver cancer	6.39e-05	0.00029	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PIK3CD—liver cancer	6.14e-05	0.000278	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ALB—liver cancer	6.07e-05	0.000275	CbGpPWpGaD
Risedronate—PTGS2—Disease—CDKN1B—liver cancer	6e-05	0.000272	CbGpPWpGaD
Risedronate—PTGS2—Disease—CTNNB1—liver cancer	5.67e-05	0.000257	CbGpPWpGaD
Risedronate—PTGS2—Disease—CDKN1A—liver cancer	5.54e-05	0.000251	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PIK3CB—liver cancer	5.36e-05	0.000243	CbGpPWpGaD
Risedronate—PTGS2—Disease—STAT3—liver cancer	4.94e-05	0.000224	CbGpPWpGaD
Risedronate—PTGS2—Disease—MYC—liver cancer	4.59e-05	0.000208	CbGpPWpGaD
Risedronate—PTGS2—Disease—TGFB1—liver cancer	4.58e-05	0.000208	CbGpPWpGaD
Risedronate—PTGS2—Disease—KRAS—liver cancer	4.24e-05	0.000192	CbGpPWpGaD
Risedronate—PTGS2—Disease—PIK3CA—liver cancer	3.9e-05	0.000177	CbGpPWpGaD
Risedronate—PTGS2—Disease—HRAS—liver cancer	3.61e-05	0.000163	CbGpPWpGaD
Risedronate—PTGS2—Disease—IL6—liver cancer	3.45e-05	0.000156	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PIK3CA—liver cancer	3.26e-05	0.000148	CbGpPWpGaD
Risedronate—PTGS2—Disease—AKT1—liver cancer	3.18e-05	0.000144	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—AKT1—liver cancer	2.67e-05	0.000121	CbGpPWpGaD
